S&P 500 Technology Sector SEC Filings — June 09, 2026

09-06-2026

Micron Technology has appointed Dr. Alexis Black Björlin to its board of directors, effective June 9, 2026. Dr. Björlin is a seasoned technology executive with expertise in AI infrastructure, cloud platforms, and semiconductors. No financial terms were disclosed, and no director departures or other negative changes were announced in this filing.

09-06-2026

J M Smucker Co reported net sales of $9,050.9M for fiscal year 2026, up 4% from $8,726.1M in 2025, driven by strong growth in U.S. Retail Coffee (+18%) and Away From Home (+15%). However, gross profit declined 10% to $3,034.5M, and the company reported a net loss of $138.7M (improved from a $1,230.8M loss in 2025), while adjusted earnings per share fell 10% to $9.15. Segment performance was mixed, with Sweet Baked Snacks sales dropping 18% and segment profit plunging 56%.

• · Net sales excluding divestitures and foreign currency exchange rose 5% to $9,047.6M.
• · Gross profit margin contracted to 33.5% from 38.8%.
• · Goodwill impairment charges were 5.6% of net sales in 2026 vs. 19.0% in 2025.
• · Other intangible assets impairment charges were 5.0% of net sales in 2026 vs. 3.7% in 2025.
• · Segment profit margins: U.S. Retail Coffee fell to 21.2% from 28.3%; Sweet Baked Snacks dropped to 10.0% from 18.6%.
• · Net cash used for investing activities was $258.8M in 2026 vs. $100.3M in 2025.
• · Net cash used for financing activities was $1,226.5M in 2026 vs. $1,102.7M in 2025.
• · Capital expenditures were $317.4M in 2026 vs. $393.8M in 2025.
• · Total capital (debt plus equity) decreased to $12,507.5M from $13,760.2M.
• · Projected principal payments for FY 2027 are $150.0M; dividend payments $469.3M; capital expenditures $325.0M; interest payments $343.2M.
• · Long-term debt obligations total $6,603.2M, with $150.0M due in 2027, $1,250.0M in 2028-2029, $500.0M in 2030-2031, and $4,703.2M in 2032 and beyond.
• · Total contractual obligations (debt, interest, purchase obligations) amount to $13,824.4M.

09-06-2026

MultiSensor AI Holdings, Inc. filed a DEFA14A supplement to its proxy statement to correct a clerical error in the number of shares of common stock issued, outstanding, and entitled to vote as of the record date for the June 12, 2026 annual meeting. The corrected figure is 2,019,434 shares, up from the previously reported 2,012,293 shares. The supplement does not modify any other information in the proxy statement.

• · The correction was due to a clerical error in the original proxy statement filed on April 24, 2026.
• · The supplement was filed on June 9, 2026, three days before the annual meeting scheduled for June 12, 2026.
• · Stockholders who have already submitted a proxy do not need to take action unless they wish to change their vote.
• · The corrected proxy materials are available at www.cstproxy.com./multisensorai/2026 and on the SEC's website.

09-06-2026

Klaviyo held its 2026 annual meeting on June 9, 2026, where stockholders elected three Class III directors (Jennifer Ceran, Chano Fernández, and Susan St. Ledger) and approved, on a non-binding advisory basis, the compensation of named executive officers. The appointment of Deloitte & Touche LLP as independent auditor for fiscal year 2026 was also ratified. All proposals passed with overwhelming support, with director votes ranging from 1.491 billion to 1.510 billion votes 'for' and minimal opposition.

• · The annual meeting was held virtually via live audio webcast.
• · All three director nominees were elected to hold office until the 2029 annual meeting.
• · Executive compensation was approved on a non-binding advisory basis with 1.494 billion votes for and 18.3 million against.
• · Ratification of Deloitte & Touche LLP as auditor for fiscal year ending December 31, 2026 passed with 1.537 billion votes for and only 428,789 against.
• · No other matters were submitted to or voted on at the meeting.

09-06-2026

Aditxt, Inc. entered into a Note Purchase Agreement on June 3, 2026, issuing $725,000 in new senior secured convertible notes (plus consolidation of existing notes) to investors, with a 35% original issue discount. The subsidiary Ignite Proteomics LLC granted a security interest in substantially all its assets, and Aditxt pledged its equity in Ignite as collateral. The filing also includes representations that the company is not insolvent and has no undisclosed material adverse events, but the heavy discount and reliance on secured debt highlight significant financial strain.

• · The new Notes consolidate $3,194,444.44 in Existing March Notes (10% OID) and $1,250,000 in Existing April Notes (25% OID).
• · Ignite Proteomics LLC granted a security interest in substantially all its assets as collateral.
• · Aditxt pledged its equity in Ignite Proteomics LLC as collateral.
• · The offering is exempt from registration under Section 4(a)(2) and Rule 506(b) of Regulation D.
• · The filing includes representations that the company is not insolvent and has no undisclosed material adverse events.

09-06-2026

MoonLake Immunotherapeutics held its 2026 Annual General Meeting on June 4, 2026, where shareholders approved all proposals, including the election of Class I director Spike Loy, ratification of Baker Tilly US, LLP as independent auditor, an advisory vote on executive compensation, and an amendment to the 2022 Equity Incentive Plan. The plan amendment increases the share reserve by 5,000,000 Class A ordinary shares, removes liberal share recycling, imposes a one-year minimum vesting requirement, and extends the plan term to June 4, 2036. All proposals received strong shareholder support, with the advisory vote on executive compensation receiving 50,365,168 votes for and only 731,158 against, indicating broad approval of the company's compensation practices.

• · The amended plan extends the term to June 4, 2036, and incorporates a one-year minimum vesting requirement for all awards.
• · The plan amendment removes liberal share recycling provisions and revises non-employee director compensation limits.
• · All proposals passed with strong majorities; the lowest support was for the advisory executive compensation vote (approximately 98.6% of votes cast in favor).
• · The company is incorporated in the Cayman Islands and its Class A ordinary shares trade on the Nasdaq Capital Market under ticker MLTX.

09-06-2026

Lafayette Square USA, Inc. held its annual meeting on June 3, 2026, where stockholders elected Sashi Brown and Jamila Mayfield as Class II directors and ratified Ernst & Young LLP as the independent auditor for fiscal year 2026. Both proposals passed unanimously with 21,530,729 votes for each director and the auditor ratification, though the auditor ratification had 1,138,021 abstentions.

• · The annual meeting was held on June 3, 2026, with a record date of April 23, 2026.
• · Proposal 1: Election of Class II directors — both nominees received 21,530,729 votes for and 0 against, with 0 broker non-votes.
• · Proposal 2: Ratification of Ernst & Young LLP as auditor — 21,530,729 votes for, 0 against, 1,138,021 abstentions, and 0 broker non-votes.
• · The company is an emerging growth company and has elected not to use the extended transition period for complying with new or revised financial accounting standards.

09-06-2026

Diana Shipping Inc. (NYSE: DSX) filed an amendment to its tender offer statement, disclosing that its wholly-owned subsidiary, 4 Dragon Merger Sub Inc., beneficially owns 6,264,548 shares of Genco Shipping & Trading Limited (NYSE: GNK), representing 14.4% of Genco's outstanding common stock. Diana is urging Genco shareholders to vote against the ratification of Genco's poison pill and to elect its two independent nominees, Jens Ismar and Paul Cornell, at the upcoming annual meeting on June 18, 2026. The tender offer to purchase all outstanding shares at $24.80 per share in cash expires on June 26, 2026.

• · The tender offer is being made by 4 Dragon Merger Sub Inc., a wholly-owned subsidiary of Diana Shipping Inc.
• · The poison pill ratification is an advisory vote only, with no binding commitment to honor the result.
• · ISS recommended a vote AGAINST the poison pill ratification, citing entrenchment concerns.
• · Glass Lewis recommended a vote FOR the pill but noted that the rights plan could affect Diana's ability to complete an acquisition.
• · Diana has updated its GOLD universal proxy card to reflect its slate and recommendation.
• · Shareholders who have already voted on the previously circulated GOLD card do not need to take any additional action.
• · The annual meeting is scheduled for June 18, 2026.
• · The tender offer expires at 5:00 p.m., New York City time, on June 26, 2026, unless further extended.

09-06-2026

Maui Land & Pineapple Company, Inc. (NYSE: MLP) announced the appointment of Ryan Panopio as Chief Investment Officer, effective June 3, 2026, a newly created role to optimize its land development pipeline and drive growth. The company recently reported a 24.5% increase in revenue to $11.5 million and over $11.0 million in contracted land sales during Q1 2026, indicating strong financial momentum. However, no specific declines or flat metrics were mentioned in the filing.

• · Ryan Panopio, age 46, previously served as Head of Capital Markets, Americas at Lendlease Group (Oct 2023 – Jan 2026) and Senior Director of Capital Transactions and FP&A at Google Development Ventures (Mar 2020 – Sep 2023).
• · He also held a 14-year tenure at SunCal Companies in various leadership roles.
• · The company holds over 22,000 acres of land and approximately 247,000 square feet of commercial real estate.
• · Assets include land within the Kapalua Resort, home to luxury hotels, beaches, trails, and the Pu‘u Kukui Watershed.

09-06-2026

Broadcom Inc. reported strong Q2 FY26 results with total net revenue of $22,187M, up 48% YoY from $15,004M, driven primarily by the products segment which surged 64% to $16,892M. Net income nearly doubled to $9,310M (EPS diluted $1.91) vs $4,965M ($1.03) in the prior-year quarter. However, operating cash flow saw a significant working capital drag, with trade receivables growing $3,685M and inventory building $2,058M in the first half of fiscal 2026, while restructuring charges continued at $10M in the quarter.

• · H1 FY26 total net revenue was $41,498M vs $29,920M in H1 FY25, an increase of 38.7%.
• · Inventory more than doubled to $4,328M from $2,270M at year-end, a 90.7% increase in six months.
• · Trade accounts receivable increased 51.6% from $7,145M to $10,830M, reflecting significant working capital investment.
• · Stock-based compensation was $4,268M in H1 FY26 vs $3,051M in H1 FY25, up 39.8%.
• · Dividends paid in H1 FY26 were $6,178M vs $5,559M in H1 FY25, up 11.1%.
• · Total stockholders' equity rose from $81,292M at Nov 2025 to $87,691M at May 2026.
• · Amortization of acquisition-related intangible assets totaled $1,461M in Q2 FY26, roughly flat with $1,483M a year ago.
• · Restructuring charges in Q2 FY26 were $10M, down from $28M in Q2 FY25.

09-06-2026

Esquire Financial Holdings, Inc. (ESQ) announced on June 9, 2026, that it has received all regulatory approvals for its merger with Signature Bancorporation, Inc. The merger is proceeding toward closing, with a joint proxy statement/prospectus already mailed to shareholders on May 11, 2026. While the receipt of approvals is a positive milestone, the filing contains extensive forward-looking risk factors, including potential failure to close, integration challenges, and dilution from issuing additional shares.

• · The joint proxy statement/prospectus was mailed to stockholders of Esquire and shareholders of Signature on or about May 11, 2026.
• · Esquire's common stock is traded on Nasdaq under the symbol ESQ.
• · The merger agreement is subject to conditions including shareholder approvals and other customary closing conditions.
• · Esquire filed a registration statement on Form S-4 with the SEC in connection with the proposed transaction.
• · Risk factors include potential adverse effects on ESQ's stock price, integration difficulties, and dilution from issuing additional shares.